Fierce Pharma June 24, 2024
In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
The result appears to be a best-case scenario for Alnylam, but analysts are still eager to see detailed data from Amvuttra’s combination with Pfizer’s tafamidis.
In the go-big-or-go-home HELIOS-B trial, Alnylam’s Amvuttra (vutrisiran) reduced the risk of death or recurrent cardiovascular events by 28% compared with placebo in the overall ATTR-CM study population, including those who were on background treatment with Pfizer’s standard-of-care blockbuster tafamidis, up to 36 months.
For the 60% of trial participants who weren’t on tafamidis—sold commercially as Vyndaqel or Vyndamax—the...
Today's Sponsors
Today's Sponsor